Savient Announces Multiple Abstracts Related to KRYSTEXXA® to be Presented at the 2013 ACR/ARHP Annual Meeting

Savient Announces Multiple Abstracts Related to KRYSTEXXA® to be Presented at
                       the 2013 ACR/ARHP Annual Meeting

PR Newswire

BRIDGEWATER, N.J., Oct. 3, 2013

BRIDGEWATER, N.J., Oct. 3, 2013 /PRNewswire/ -- Savient Pharmaceuticals,
Inc.(Nasdaq: SVNT) today announced that several abstracts related to
KRYSTEXXA^®(pegloticase) have been selected for presentation at the American
College ofRheumatology(ACR) / Association of Rheumatology Health
Professionals (ARHP) 2013 Annual Meeting. The 2013 ACR/ARHP annual meeting
will be held October 26-30, 2013, inSan Diego, CA.

Full text of the following accepted abstracts can be accessed by visiting
theAmerican College of Rheumatologywebsite

  oPharmacokinetics and Pharmacodynamics Of Pegloticase In Patients With
    End-Stage Renal Failure Receiving Hemodialysis; Abstract #1176 (Poster);
    Monday, October 28, 2013, 8:30am – 4:00pm PT
  oPharmacovigilance Update On Pegloticase For Treatment Refractory Gout:
    United States Clinical Experience Demonstrates The Value Of Serum Uric
    Acid Monitoring As a Biomarker Of Risk and Efficacy; Abstract #1192
    (Poster); Monday, October 28, 2013, 8:30am – 4:00pm PT
  oTarget Tophus Size and Complete Response Rates In Patients Treated With
    Open-Label Pegloticase For Chronic Gout Refractory To Conventional
    Therapy; Abstract #1193 (Poster); Monday, October 28, 2013, 8:30am –
    4:00pm PT
  oMany Gout Patients Treated By Rheumatologists Do Not Meet Established
    Treatment Goals Despite Long-Term Urate Lowering Therapy: Results Of a
    Gout Patient Encounter Survey; Abstract #861 (Oral); Sunday, October 27,
    2013, 5:45pm PT

Savient Pharmaceuticals, a specialty biopharmaceutical company focused
on developing and commercializing KRYSTEXXA^®(pegloticase) for the treatment
of chronic gout in adult patients who do not respond to conventional therapy.
Savient has exclusively licensed worldwide rights to the technology related to
KRYSTEXXA and its uses fromDuke University("Duke") andMountain View
Pharmaceuticals, Inc.("MVP").Dukedeveloped the recombinant uricase enzyme
and MVP developed the PEGylation technology used in the manufacture of
KRYSTEXXA. MVP andDukehave been granted U.S. and foreign patents disclosing
and claiming the licensed technology and, in addition, Savient owns or co-owns
U.S. and foreign patents and patent applications, which collectively form a
broad portfolio of patents covering the composition, manufacture and methods
of use and administration of KRYSTEXXA. In the U.S., Savient also supplies
Oxandrin^®(oxandrolone tablets, USP) CIII and co-promotes
Kineret^®(anakinra) with Swedish Orphan Biovitrum AB (Sobi). For more
information, please visit the Company's website

Certain information in this press release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that are not
statements of historical fact should be considered forward-looking statements.
We often use words such as "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe," "may," "predict," "will," "would," "could,"
"should," "target" and similar expressions to identify forward-looking
statements. Actual results or events could differ materially from those
indicated in forward-looking statements as a result of risks and
uncertainties. For a discussion of some of the risks and important factors
that we believe could cause actual results or events to differ from the
forward-looking statements that we make, see the sections entitled "Risk
Factors" and "Management's Discussion and Analysis of Financial Condition and
Results of Operations" in our Quarterly Report on Form 10-Q for the quarter
endedJune 30, 2013. In addition, new risks and uncertainties emerge from time
to time, and it is not possible for the Company to predict or assess the
impact of every factor that may cause its actual results or events to differ
from those contained in any forward-looking statements.Accordingly, you
should not place undue reliance on any forward-looking statements contained in
this press release.Any forward-looking statements speak only as of the date
of this press release. We undertake no obligation to publicly update
forward-looking statements, whether as a result of new information, future
events or otherwise.



Savient Pharmaceuticals, Inc.            Burns McClellan
John P. Hamill                           Caitlyn E. Murphy
Co-President and Chief Financial Officer                  (212) 213-0006
(732) 418-9300

SOURCE Savient Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.